MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

MeiraGTx Holdings plc MGTX has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX).

  • Xerostomia, or Dry mouth, happens when a person cannot make enough saliva (spit).
  • 6 of the 7 participants who reached the Day 90 assessment reported their symptoms of dry mouth as better following treatment.
  • All 6 of these participants rated changes in xerostomia scores (2 or more).
  • 3 participants rated the change in xerostomia symptoms with the highest level of improvement (scores of 6 or 7)
  • Improvement in xerostomia symptoms persisted through 1 year in two of the patients who reached Day 360.
  • Participant 1-1 has just reached the 24-month assessment, and the highest possible score of 7 was maintained.
  • Participant 2-1 reported no improvement and was the only one of the 7 participants who had no saliva production at baseline.
  • The Company plans to initiate a Phase 2 study evaluating two active doses of AAV2-hAQP1 in 2H of 2022
  • The Company says that no new medications for RIX have been approved in over 20 years.
  • Price Action: MGTX shares closed at $17.05 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!